Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators. N Engl J Med. 2006 Nov 16;355(20):2099-112
Related Articles:
- Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
- Hypertonic Saline for Hyponatremia: Risk of Inadvertent Overcorrection.
Recent Comments